1Raptopoulou A,Sidiropoulos P,Katsouraki M. Anti-citrulline antibodies in the diagnosis and prognosis of rheumatoid arthritis:evolving concepts[J].Critical Reviews in Clinical Laboratory Sciences,2007.339-363.
2Schellekens GA,Visser H,De Jong BA,et al.The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide[J].Arthritis Rheum,2000,43:155-163.
3Nicala B,Giovanni M,Elio T,et al.Diagnosic accuracy of the anticitrulline antibody for Rheumatoid Arthtitis[J].Clinical Chemistry,2001,47 (5):1089-1093.
4Kroot EJJA,de Jeug BAW,van Leeuwen MA,et al.The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recentonset rheumatoid arthritis[J].Arthritis Rheum,2000,43:1831-1835.
7van Vollenhoven R F, Severens J L. Observational studies: a valua- ble source for data on the true value of RA therapies[ J]. Clin Rheu- matol, 2011,30 ( 1 ) : S19- S24.
8Karkucak M, Capkin E, Ozsu S, et al. An evaluation ofthe tubercu- lin skin test for anti TNF alpha prophylaxis in patients with ankylo-sing spondylitis and rheumatoid arthritis [ J ]. Bratisl Lek Listy, 2010, 111 (9) :498-501.
9Shirinskii I V, Zheltova 0 I, Shirinskii V S, et al. Relationship be- tween blood lipid spectrum and activity ofthe disease in patients with rheumatoid arthritis[J]. Klin Med ( Mosk), 2008,86(12) :40-43.
10Kiely P, Walsh D, Williams R,et al. Outcome in rheumatoid arthri- tis patients with continued conventional therapy for moderate disease activity-theearly RA network ( ERAN ) [ J ]. Rheumatology ( Ox- ford), 2011,50(5) :926-931.
